Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued
Raindog is the production company founded by Oscar®-winning actor Colin Firth and former Sony Music CEO Ged Doherty, now joined by writer/producer Trish D Chetty Building on the platform of a robust award-winning film track-record, Raindog will expand into TV drama, music content and documentaries The UK Creative Content EIS Fund has invested in Raindog … Continued
Starling is one of the UK’s leading digital banks and the campaign marks the first piece of work from the brand’s new agency line-up of Wonderhood Studios and media agency Bountiful Cow. In 2018 Starling became the first mobile bank to launch business accounts, with no monthly fees and an in-app marketplace, allowing business owners … Continued
Food giant Mizkan has announced that Wonderhood Studios will take over its creative account from Mcgarrybowen, focusing on advertising for the firm’s food portfolio. This includes Branston Pickle which is coming up to its 100-year anniversary. Vanni Cataldi, Mizkan’s head of marketing, said: “I was really impressed by Alex [Best, Wonderhood Studios’ chief operating officer] and … Continued
Idea management scaleup Wazoku has made two new senior hires, as the company readies itself for further growth in 2020. Kathryn Layland joins as Chief Revenue Officer (CRO) based in Wazoku’s London HQ, while Alex Butucea arrives as Wazoku’s new Director of Software Engineering, in the company’s Bristol office. Layland has held senior global revenue positions with several AdTech solution providers and has experience of growing and scaling SaaS … Continued
BBC news reported on Foamstream, the herbicide-free weed control product of Weedingtech, and its use across council parks and other public spaces. Leo de Montaignac, Chief Executive of Weedingtech, was quoted in the article: “I think that we’re only just seeing the very start of this market, and I think that over the next couple … Continued
Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed a collaboration and non-exclusive research agreement with a US-based, clinical stage antibody company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) including those that have been enhanced with Scancell’s proprietary AvidiMab™ technology. This is the … Continued
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. 03.01.20 It was the year of Brexit (again), another bruising general election, and trauma in the retail fund industry with the demise of Woodford and the … Continued
Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid tumours. Dose-escalation is the first part of the Phase I program that includes two U.S. … Continued
Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus Capital has sold their investment in London-based marketing agency Once Upon a Time (OUAT) in a deal which delivered a 1.8x share price return on investment not … Continued
Calculus Capital are delighted to shortlisted for “Best EIS Fund Manager” at the EISA awards. “The EIS Association Awards denote excellence in a number of EIS/SEIS fields. The Awards will be presented at our Chairman’s Reception at the House of Lords on Tuesday 6th February 2018 to those individuals and companies in the EIS and … Continued
Avvio Co-founder and CEO, Frank Reeves discusses the impact of AI on improving hotel booking rates on the travel technology show. Avvio recently launched Allora, the worlds first booking platform powered by artificial intelligence.
Award winning private equity fund manager Calculus Capital strengthens investment team with senior hire Calculus Capital, the private equity firm and pioneer of Enterprise Investment Scheme (‘EIS’) funds, is pleased to announce the appointment of Alexander Crawford as Investment Director. Alexander has over 20 years’ corporate finance experience, including ten years with Robert Fleming & … Continued
Calculus was proud to support the FT Triathlon, run by our portfolio company Human Race. Well done to Roshan Puri and Claire Cherry who represented Calculus at the event. A special congratulations to our investment analyst Claire who stormed to win the women’s sprint triathlon in an impressive time of 1:27:56 for a 750m swim, … Continued
Calculus Capital, the specialist in creating and managing private equity funds for individuals, is pleased to announce the appointment of Robert Davis as Investment Director. Robert joins from Avendus Capital, where he has spent the last three years as a Managing Director and Head of European Business. A graduate from St John’s College, Cambridge, Robert … Continued
We are proud to announce that we are sponsoring the FT Triathlon run by Human Race, which takes place on Saturday 13th September at Dorney Lake, Windsor. The Financial Times Triathlon is in support of Impetus – The Private Equity Foundation. Calculus are entering a team and will be sponsoring the goody bags given out … Continued
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. … Continued
Calculus Capital continues to boost its investment team with the appointment of Richard Moore, formerly of Citigroup, as Investment Director Calculus Capital (“Calculus”) is pleased to announce that Richard Moore has joined their investment team. Richard joins from Citigroup where he worked from 2005 to 2013, most recently as the Head of the European Technology … Continued